In patients with advanced non‑small cell lung cancer (NSCLC) or colorectal cancer, should I test for KEAP1 mutations, and how does a pathogenic KEAP1 alteration affect prognosis and treatment decisions?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 26, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

KEAP1 Mutations in Advanced NSCLC and Colorectal Cancer

KEAP1 mutations should be tested as part of broad molecular profiling in advanced non-squamous NSCLC, but routine testing is not currently recommended for colorectal cancer based on available guidelines.

Testing Recommendations

Non-Small Cell Lung Cancer

Broad molecular profiling that includes KEAP1 is strongly recommended for all patients with advanced or metastatic NSCLC 1. The 2024 NCCN guidelines emphasize that broad molecular profiling should identify all actionable molecular biomarkers and optimally also identify emerging biomarkers like KEAP1 1.

  • Non-squamous NSCLC: Testing is recommended for all patients with adenocarcinoma, large cell carcinoma, and NSCLC not otherwise specified 1
  • Squamous cell carcinoma: The same molecular testing should be considered, as cumulative incidence of targetable alterations ranges from 2-10% 1
  • Testing methods: Both tissue biopsy and/or plasma testing are acceptable; concurrent testing can improve time to results 1

KEAP1 has been identified as a loss-of-function mutation in both adenocarcinoma and squamous cell carcinoma through large-scale genomic studies 2. Recent UK guidelines specifically recommend that KEAP1 mutations be included in NGS panel reporting as they are associated with specific resistance to immune checkpoint inhibitors 3.

Colorectal Cancer

There is no guideline evidence supporting routine KEAP1 testing in colorectal cancer. The provided evidence focuses exclusively on NSCLC, and KEAP1 mutations have not been established as clinically actionable in colorectal cancer management.

Prognostic Impact of KEAP1 Mutations

Overall Survival and Disease Aggressiveness

KEAP1 mutations are associated with significantly worse prognosis in NSCLC across all disease stages 4:

  • Localized disease (UICC I-IIIA): KEAP1 mutations are independent negative prognostic markers (HR 1.68,95% CI: 1.24-2.26, p=0.001) 4
  • Advanced disease (UICC IIIB-IV): KEAP1 mutations remain a negative prognostic factor (HR 1.40,95% CI: 1.23-1.61, p<0.001) 4
  • The increased relative hazard of harboring KEAP1 mutations is comparable to an increase in one UICC stage 4

Co-occurring Mutations

KEAP1 mutations frequently co-occur with KRAS mutations and define an aggressive disease subset 5, 6:

  • Approximately 20-30% of patients with metastatic NSCLC display primary resistance to immune checkpoint inhibitors, with KEAP1 mutations being a major contributor 5
  • KEAP1 mutations are associated with an aggressive disease phenotype and resistance to standard ICI regimens 5

Treatment Implications

Immunotherapy Resistance

KEAP1 mutations predict poor response to immune checkpoint inhibitor monotherapy 3, 5:

  • KEAP1 mutations are associated with specific resistance to immune checkpoint inhibitors 3
  • In squamous cell NSCLC with NFE2L2 and/or KEAP1 mutations, patients had significantly shorter real-world progression-free survival (4.54 vs 6.25 months, p=0.003) following first-line therapy 7
  • No survival differences were observed in patients with KEAP1 mutations receiving first-line anti-PD-1/PD-L1 therapies versus other therapies in squamous cell NSCLC 7

Combination Immunotherapy Strategy

For KEAP1-mutant NSCLC, dual immunotherapy (anti-PD-1/anti-CTLA-4) combined with chemotherapy may be more effective than immunotherapy or chemotherapy alone 6:

  • Single-agent immunotherapy shows limited efficacy in KEAP1-mutant tumors
  • Combination approaches targeting multiple immune checkpoints may overcome the immunologically "cold" tumor microenvironment
  • This represents an emerging treatment strategy requiring prospective validation 6

EGFR TKI Resistance

In EGFR-mutant NSCLC, co-occurring KEAP1/NFE2L2/CUL3 mutations predict intrinsic resistance to EGFR tyrosine kinase inhibitors 8:

  • Median time to treatment failure on EGFR TKI: 4.7 months with KEAP1/NFE2L2/CUL3 mutations vs 13.0 months without (p=0.0014) 8
  • These mutations represent a mechanism of intrinsic resistance to TKI treatment 8

Radiation Therapy Considerations

KEAP1 mutations predict radioresistance in localized NSCLC 9:

  • KEAP1 and NFE2L2 mutations are predictive of high rates of local recurrence after radiotherapy but not surgery 9
  • Approximately half of all local recurrences after radiotherapy are associated with these mutations 9
  • Glutaminase inhibition may allow personalized radiosensitization of KEAP1-mutant tumors 9

Emerging Targeted Approaches

KEAP1-deficient NSCLC shows enhanced vulnerability to ATR inhibitors 10:

  • KEAP1-NRF2 pathway drives compensatory modulation of ATR-CHK1 signaling 10
  • ATR inhibitors show enhanced anti-tumor activity in KEAP1-deficient NSCLC models 10
  • ATR inhibitors synergize with gemcitabine and enhance antitumor immunity 10
  • In the HUDSON trial, LKB1/KEAP1-deficient NSCLC patients demonstrated enhanced benefits to ceralasertib (ATRi) plus durvalumab 10

Clinical Algorithm for KEAP1-Mutant Advanced NSCLC

  1. Initial diagnosis: Perform broad molecular profiling including KEAP1 on all advanced NSCLC patients 1

  2. If KEAP1 mutation detected:

    • Check for co-occurring mutations (KRAS, STK11/LKB1, TP53, EGFR) 5, 4
    • Counsel patient about worse prognosis (comparable to one stage increase) 4
  3. Treatment selection:

    • If EGFR-mutant: Expect shorter TKI response; consider earlier transition to alternative therapies 8
    • If no actionable driver: Avoid single-agent immunotherapy; prioritize chemotherapy-immunotherapy combinations or dual checkpoint inhibitor combinations 5, 6
    • If localized disease requiring radiation: Consider surgery over radiation when feasible; if radiation necessary, consider glutaminase inhibitor combinations in clinical trial settings 9
    • Consider ATR inhibitor clinical trials, particularly if LKB1 co-mutation present 10

Important Caveats

  • Only pathogenic KEAP1 mutations (not all detected variants) are associated with radioresistance and poor outcomes 9
  • Expression of NFE2L2 target genes does not predict outcomes, underscoring the utility of tumor genotyping over gene expression analysis 9
  • KEAP1 mutations with co-occurring TP53 missense mutations may have better outcomes than KEAP1 mutations with wild-type or truncating TP53 mutations 4
  • Molecular stratification based on KEAP1 mutation status should be implemented for both localized and advanced-stage NSCLC to optimize clinical decision-making 4

References

Guideline

non-small cell lung cancer, version 4.2024, nccn clinical practice guidelines in oncology.

Journal of the National Comprehensive Cancer Network : JNCCN, 2024

Research

Comprehensive Analysis of TP53 and KEAP1 Mutations and Their Impact on Survival in Localized- and Advanced-Stage NSCLC.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2022

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.